Drug
Englumafusp Alfa
Englumafusp Alfa: highest development phase Phase 1/2, developed by Roche. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Roche
Trials
| Drug | Phase | Indication |
|---|---|---|
| Englumafusp alfa NCT04077723 | Phase 1/2 | Lymphoma, Non-Hodgkin |
Latest
No recent events.
Follow Englumafusp Alfa on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.